Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 5.25
High: 5.25
Low: 5.00
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

U.S. regulatory update

28 Mar 2011 07:02

RNS Number : 6964D
Allergy Therapeutics PLC
28 March 2011
 



Monday 28 March 2011

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

 

U.S. regulatory update

 

 

 

Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines is pleased to announce that it met with the U.S. Food and Drug Administration (FDA) for a productive discussion. The FDA has informed the Company of its intention to lift the clinical hold in order to allow the development of MATA-MPL© products to move forward. The Company expects to receive the formal communication from the FDA in the coming weeks.

 

 

Manuel Llobet, Chief Executive of Allergy Therapeutics, said:

 

"We are very pleased to have received positive feedback from the FDA and look forward to providing more information when the formal communication is received."

 

 

-Ends-

 

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Ian Postlethwaite, Finance Director

www.allergytherapeutics.com

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson/ Clare Terlouw

Financial Dynamics

+44 (0) 207 831 3113

Ben Brewerton/ Susan Quigley

 

 

 

About Pollinex® Quattro

 

Pollinex® Quattro is a four injection therapeutic vaccine which is being developed for the treatment of allergic conditions which offers same season relief in as little as three weeks after treatment. It is a family of specific standardised vaccines representing a potentially extensive franchise for Allergy Therapeutics and is a novel entrant in the multibillion dollar global allergy market. It is currently available in Europe on a named patient basis.

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDKODNFBKDDNB
Date   Source Headline
15th Jan 20217:00 amRNSBlock Listing Return and Total Voting Rights
13th Jan 20217:00 amRNSHalf Year Trading Update 2021 & Notice of Results
8th Jan 20214:41 pmRNSSecond Price Monitoring Extn
8th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSInitiation of peanut allergy biomarker study
14th Dec 20203:58 pmRNSDirector/PDMR Shareholding
8th Dec 20202:42 pmRNSResult of Annual General Meeting
20th Nov 20201:51 pmRNSGrant of Awards under Long Term Incentive Plan
20th Nov 20207:00 amRNSDirector/PDMR Shareholding
10th Nov 20207:05 amRNSAnnual Report & Accounts and AGM Notification
26th Oct 20207:00 amRNSInitiation of Grass MATA MPL exploratory study
12th Oct 20207:00 amRNSHolding(s) in Company
9th Oct 20207:00 amRNSDirector Dealings and Issue of Equity
23rd Sep 20207:00 amRNSPreliminary Results
3rd Sep 20207:00 amRNSAGY secures VLP technology platform
20th Jul 20207:30 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
15th Jul 202011:05 amRNSSecond Price Monitoring Extn
15th Jul 202011:00 amRNSPrice Monitoring Extension
15th Jul 20207:00 amRNSTrading Update
9th Jul 20207:00 amRNSInvalidation of Birch MATA MPL phase III results
1st Jul 20205:15 pmRNSTotal Voting Rights
1st Jul 20205:14 pmRNSBLOCK LISTING SIX MONTHLY RETURN
24th Jun 20204:41 pmRNSSecond Price Monitoring Extn
24th Jun 20204:36 pmRNSPrice Monitoring Extension
24th Jun 20207:00 amRNSTrading Update
18th May 20202:05 pmRNSSecond Price Monitoring Extn
18th May 20202:00 pmRNSPrice Monitoring Extension
23rd Apr 20204:41 pmRNSSecond Price Monitoring Extn
23rd Apr 20204:36 pmRNSPrice Monitoring Extension
22nd Apr 202010:11 amRNSEAACI review of adjuvants and formulations
1st Apr 20201:09 pmRNSGrant and Vesting of Awards
9th Mar 20207:15 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
4th Mar 20207:00 amRNSHalf-year Report
29th Jan 202012:00 pmRNSData for peanut allergy vaccine published in JACI
16th Jan 202012:25 pmRNSTrading Update & Notice of Results - Replacement
16th Jan 20208:00 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average
16th Jan 20207:00 amRNSHalf Year Trading Update & Notice of Results
2nd Dec 20199:57 amRNSHoldings in Company
29th Nov 201910:34 amRNSHoldings in Company
26th Nov 20197:00 amRNSUpdate to Grass MATA MPL Ph III clinical programme
25th Nov 201912:13 pmRNSResult of Annual General Meeting
22nd Oct 20199:23 amRNSAnnual Report and Accounts
26th Sep 20197:30 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Continuing to gain market share
25th Sep 20197:00 amRNSPreliminary Results
11th Jul 20197:00 amRNSTrading update
1st Jul 20197:21 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Successful legal outcome removes uncertainty
1st Jul 20197:16 amEQSHardman & Co Research: Oxford BioMedica (OXB): Eying up long-term value
27th Jun 20197:00 amRNSSuccessful Litigation Settlement
27th Jun 20197:00 amRNSTrading Statement
19th Jun 20197:00 amRNSBoard Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.